[go: up one dir, main page]

US20140088125A1 - Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease - Google Patents

Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease Download PDF

Info

Publication number
US20140088125A1
US20140088125A1 US14/113,709 US201214113709A US2014088125A1 US 20140088125 A1 US20140088125 A1 US 20140088125A1 US 201214113709 A US201214113709 A US 201214113709A US 2014088125 A1 US2014088125 A1 US 2014088125A1
Authority
US
United States
Prior art keywords
ethyl
dimethylpropan
carboxy
aminium
dimethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/113,709
Other languages
English (en)
Inventor
Ivars Kalvins
Edgars Liepins
Einars Loza
Maija Dambrova
Limars Stonans
Daina Lola
Janis Kuka
Osvalds Pugovics
Reinis Vilskersts
Solveiga Grinberga
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Grindeks JSC
Original Assignee
Grindeks JSC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grindeks JSC filed Critical Grindeks JSC
Assigned to JSC GRINDEKS reassignment JSC GRINDEKS ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DAMBROVA, MAIJA, GRINBERGA, SOLVEIGA, KALVINS, IVARS, KUKA, JANIS, LIEPINS, EDGARS, LOLA, Daina, LOZA, EINARS, PUGOVICS, OSVALDS, STONANS, ILMARS, VILSKERSTS, REINIS
Publication of US20140088125A1 publication Critical patent/US20140088125A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/06—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and acyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C07C227/08—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/12—Acetic acid esters
    • C07C69/14—Acetic acid esters of monohydroxylic compounds
    • C07C69/145—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols
    • C07C69/157—Acetic acid esters of monohydroxylic compounds of unsaturated alcohols containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/557—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. orotic acid

Definitions

  • the present invention relates to new compound 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts, and to a method of preparation thereof (compound of formula 4)
  • the present invention relates also to use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease.
  • Cardiovascular diseases are a group of disorders of the heart and blood vessels.
  • CVD cardiovascular disease
  • Myocardial infarction (heart attack) is a serious result of coronary artery disease.
  • Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia.
  • a heart attack or myocardial infarction is a medical emergency in which the supply of blood to the heart is suddenly and severely reduced or cut off, causing the muscle to die from lack of oxygen.
  • More than 1.1 million people experience a heart attack (myocardial infarction) each year, and for many of them, the heart attack is their first symptom of coronary artery disease.
  • a heart attack may be severe enough to cause death or it may be silent. As many as one out of every five people have only mild symptoms or none at all, and the heart attack may only be discovered by routine electrocardiography done some time later.
  • a heart attack (myocardial infarction) is usually caused by a blood clot that blocks an artery of the heart.
  • the artery has often already been narrowed by fatty deposits on its walls. These deposits can tear or break open, reducing the flow of blood and releasing substances that make the platelets of the blood sticky and more likely to form clots.
  • ⁇ -Butyrobetaine from which the mammalian organism synthesises carnitine, was primarily characterised as a toxic substance which accelerates respiration, causes salivation and lacrimation, pupil dilation, vasoconstriction and heart stop in diastole LINNEWEH, W. Gamma-Butyrobetain, Crotonbetain und Carnitin im tierischen Stoff Touch. Hoppe-Seylers Zeit intimid für physio strige Chemie. 1929, vol. 181, p. 42-53. At the same time, in later papers other authors ascertained that ⁇ -butyrobetaine is extremely low toxic (LD50>7000 mg/kg, s.c.) ROTZSCH, W. Iber die Toxizitat des Carnitins und utz verwandter Stoffe. Acta biol. med. germ. 1961, vol. 3, p. 28-36.
  • 3- (2,2,2-Trimethylhydrazinium) propionate dihydrate is known as compound with cardioprotective properties (this substance being known under its International Nonproprietary Name of Meldonium).
  • 3- (2,2,2-Trimethylhydrazinium) propionate is disclosed in U.S. Pat. No. 4,481,218 (INST ORGANICHESKOGO SINTEZA) 06 Nov. 1984 as well in U.S. Pat. no. 4,451,485 A (INSTITU ORCH SINTEZA AKADEMI I) 29 May 1984.
  • An object of the present invention is to provide a compound, which has pronounced cardioprotective effect.
  • 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts posses pronounced cardioprotective effect and are more effective as Meldonium dihydrate in vivo myocardial infarction models, due to this property 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts may be used in medicine.
  • 3-Carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts can be use as a solution for injection.
  • the following object of the present invention is a method of preparation of said compound of formula 4.
  • Titration assays water content (Fisher) 0.13%, betaine content (HClO 4 ) 93.0%, (E)-butenedioic acid content 46.1%.
  • 3-Carboxy-N-ethyl-N,N-dimethylpropan-1-aminium 3-carboxypropanoate was prepared in a form of a water solution.
  • ca. 90% 4-[ethyl-(dimethyl)ammonio]butanoate (3) (2.20 g, 12.44 mmol) and succinic acid (1.49 g, 12.62 mmol) were placed in a volumetric flask and dissolved and diluted with water up to 100 ml.
  • Rats were adapted to local conditions for two weeks before the start of treatment. Meldonium dihydrate at a dose of 20 mg/kg, gamma-butyrobetaine at a dose of 20 mg/kg and 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts at dose of 20 mg/kg were administered p.o. daily for 8 weeks. Control rats received water.
  • the isolated rat heart experiment was performed essentially as described earlier (Liepinsh et al., J. Cardiovasc. Pharmacol. 2006; 48(6):314-9). Twenty-four hours after the last drug administration hearts were excised and retrogradely perfused via the aorta at a constant pressure with oxygenated Krebs-Henseleit buffer at 37° C. The heart rate, left ventricle end-diastolic pressure and left ventricle developed pressure were continuously recorded. Coronary flow was measured using an ultrasound flow detector (HSE) and the PowerLab 8/30 system from ADInstruments. The hearts were perfused for 20 min to stabilize the hemodynamic functions and then occlusion was performed for 60 min by constricting threads through a plastic tube.
  • HSE ultrasound flow detector
  • Infarct Size Area of Necrosis/Area at Risk ⁇ 100%.
  • the anti-infarction effect of examined substances was investigated in an isolated rat heart infarction model.
  • the coronary flow in all experimental groups was decreased for 40% (from 11 ml/min to 7 ml/min).
  • the drop of developed left ventricular pressure for 50% was observed.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
US14/113,709 2011-04-27 2012-04-27 Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease Abandoned US20140088125A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP11163840 2011-04-27
EP11163871.4 2011-04-27
EP11163872 2011-04-27
EP11163872.2 2011-04-27
EP11163871 2011-04-27
EP11163841.7 2011-04-27
EP11163839 2011-04-27
EP11163840.9 2011-04-27
EP11163839.1 2011-04-27
EP11163841 2011-04-27
PCT/EP2012/057806 WO2012146736A1 (en) 2011-04-27 2012-04-27 Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2012/057806 A-371-Of-International WO2012146736A1 (en) 2011-04-27 2012-04-27 Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US15/828,660 Continuation US10351534B2 (en) 2011-04-27 2017-12-01 Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease

Publications (1)

Publication Number Publication Date
US20140088125A1 true US20140088125A1 (en) 2014-03-27

Family

ID=46062261

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/113,709 Abandoned US20140088125A1 (en) 2011-04-27 2012-04-27 Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
US15/828,660 Active US10351534B2 (en) 2011-04-27 2017-12-01 Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
US15/828,660 Active US10351534B2 (en) 2011-04-27 2017-12-01 Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease

Country Status (25)

Country Link
US (2) US20140088125A1 (pt)
EP (1) EP2702033B1 (pt)
JP (1) JP5997762B2 (pt)
KR (1) KR20130138827A (pt)
CN (1) CN103608326B (pt)
AU (1) AU2012247467B2 (pt)
BR (1) BR112013027065B1 (pt)
CA (1) CA2832693C (pt)
CY (1) CY1117890T1 (pt)
DK (1) DK2702033T3 (pt)
EA (1) EA023547B1 (pt)
ES (1) ES2585558T3 (pt)
GE (1) GEP20156373B (pt)
HR (1) HRP20160998T1 (pt)
HU (1) HUE030415T2 (pt)
IL (1) IL228891A (pt)
LT (1) LT2702033T (pt)
MX (1) MX351765B (pt)
PE (1) PE20140777A1 (pt)
PL (1) PL2702033T3 (pt)
PT (1) PT2702033T (pt)
RS (1) RS55092B1 (pt)
SI (1) SI2702033T1 (pt)
SM (1) SMT201600416B (pt)
WO (1) WO2012146736A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3117B1 (ar) * 2012-12-20 2017-09-20 Grindeks Jsc استعمال 3- كربوكسي- ن-إيثيل- ن، ن- ثاني ميثيل بروبان-1– أمينيوم أو ملح منه مقبول صيدلانياً في معالجة تصلب الشرايين
JO3333B1 (ar) 2013-09-26 2019-03-13 Grindeks Jsc استعمال 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium أو ملح مقبول دوائيا منه للوقاية من السكري وعلاجه

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017611A (en) * 1987-03-25 1991-05-21 Bremanis Gunar A Ethyl-3-(2-ethyl-2,2-dimethylhydrazinium)-propionate salts to treat arrhythmia
WO1997006795A1 (en) * 1995-08-21 1997-02-27 Ivars Kalvinsh Pharmaceutical compositions containing gamma-butyrobetain for treatment of blood flow disorders
EP1103259A1 (de) * 1999-11-25 2001-05-30 Basf Aktiengesellschaft Verwendung von y-Butyrobetain Salzen zur Herstellung von Zubereitungen für die menschliche und tierische Ernährung
WO2009071586A2 (en) * 2007-12-05 2009-06-11 Grindeks, A Joint Stock Company 3-(2,2,2-trimethylhydrazinium) propionate salts for treating ischemic heart disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1103259A (en) * 1913-04-23 1914-07-14 John J Buckley Fly-paper holder.
GB1238868A (pt) 1967-08-08 1971-07-14
SU997646A1 (ru) 1978-11-27 1983-02-23 Ордена Трудового Красного Знамени Институт Органического Синтеза Ан Латвсср Кормова добавка
IT1210935B (it) 1981-09-17 1989-09-29 Inst Orch Sinteza Akademi Nauk Composizione farmaceutica per il trattamento di malattie cardiovascolari.
JP3119430B2 (ja) * 1995-07-25 2000-12-18 大鵬薬品工業株式会社 水酸基ラジカル消去剤
LV11728B (en) * 1995-08-21 1997-08-20 Kalvins Ivars Pharmaceutical composition
US5973026A (en) 1998-02-02 1999-10-26 Xerox Corporation Ink jet inks
UA82540C2 (uk) * 2003-08-04 2008-04-25 "Джоінт Сток Компані Гріндекс" Солі мелдонію, спосіб їх одержання і фармацевтична композиція (варіанти) на їх основі
CA2508094A1 (en) 2005-05-20 2006-11-20 Vivier Canada Inc. Composition for accelerating collagen synthesis
US7863274B2 (en) 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
LV13705B (en) 2006-11-06 2008-07-20 Ivars Kalvins Process for producing high purity intermolecular salt of 3-carboxy-n,n,n-trimethyl-propane-1-amine hydroxide
JP4761265B2 (ja) 2007-10-17 2011-08-31 学校法人甲南学園 核酸合成を促進する化合物を含む組成物およびその利用、並びに当該化合物の製造方法
EP2070529B1 (en) * 2007-12-12 2011-10-12 Grindeks, a joint stock company Medical use of 3-(2,2,2-trimethylhydrazinium) propionate orotate
WO2010151095A1 (en) * 2009-06-25 2010-12-29 Tetra, Sia Novel acetylsalicylic acid salts
WO2010149654A1 (en) * 2009-06-25 2010-12-29 Grindeks, A Joint Stock Company Pharmaceutical composition of gamma-butyrobetaine or a pharmaceutically acceptable salt and meldonium or a pharmaceutically acceptable salt
LV14345B (lv) * 2009-10-22 2011-07-20 Grindeks, A/S 4-[Etil(dimetil)amonija]butanoāts un tā izmantošana kardiovaskulāro slimību ārstēšanai

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017611A (en) * 1987-03-25 1991-05-21 Bremanis Gunar A Ethyl-3-(2-ethyl-2,2-dimethylhydrazinium)-propionate salts to treat arrhythmia
WO1997006795A1 (en) * 1995-08-21 1997-02-27 Ivars Kalvinsh Pharmaceutical compositions containing gamma-butyrobetain for treatment of blood flow disorders
EP1103259A1 (de) * 1999-11-25 2001-05-30 Basf Aktiengesellschaft Verwendung von y-Butyrobetain Salzen zur Herstellung von Zubereitungen für die menschliche und tierische Ernährung
WO2009071586A2 (en) * 2007-12-05 2009-06-11 Grindeks, A Joint Stock Company 3-(2,2,2-trimethylhydrazinium) propionate salts for treating ischemic heart disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Machine translation of EP 1,103,259 A1 obtained from EPO website (05-2001). *

Also Published As

Publication number Publication date
SI2702033T1 (sl) 2016-09-30
MX351765B (es) 2017-10-26
KR20130138827A (ko) 2013-12-19
MX2013012551A (es) 2015-04-10
ES2585558T3 (es) 2016-10-06
PL2702033T3 (pl) 2017-04-28
BR112013027065A2 (pt) 2016-12-27
LT2702033T (lt) 2016-09-12
JP2014523403A (ja) 2014-09-11
US20180079728A1 (en) 2018-03-22
CA2832693A1 (en) 2012-11-01
WO2012146736A1 (en) 2012-11-01
NZ616467A (en) 2015-10-30
AU2012247467B2 (en) 2016-07-28
EA201301080A1 (ru) 2014-02-28
US10351534B2 (en) 2019-07-16
CN103608326B (zh) 2016-01-20
CY1117890T1 (el) 2017-05-17
HUE030415T2 (en) 2017-05-29
AU2012247467A1 (en) 2013-11-14
CA2832693C (en) 2018-10-02
PT2702033T (pt) 2016-08-17
PE20140777A1 (es) 2014-07-20
EA023547B1 (ru) 2016-06-30
EP2702033B1 (en) 2016-06-08
EP2702033A1 (en) 2014-03-05
WO2012146736A8 (en) 2013-03-28
GEP20156373B (en) 2015-09-25
CN103608326A (zh) 2014-02-26
IL228891A (en) 2015-11-30
HRP20160998T1 (hr) 2016-10-21
JP5997762B2 (ja) 2016-09-28
WO2012146736A4 (en) 2013-01-31
BR112013027065B1 (pt) 2019-12-03
RS55092B1 (sr) 2016-12-30
SMT201600416B (it) 2017-01-10
IL228891A0 (en) 2013-12-31
DK2702033T3 (en) 2016-08-29

Similar Documents

Publication Publication Date Title
US9573882B2 (en) Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease
AU2004260779B2 (en) Meldonium salts, method of their preparation and pharmaceutical composition on their basis
US10351534B2 (en) Use of 3-carboxy-N-ethyl-N,N-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
JP2883187B2 (ja) Ｌ―カルニチンとγ―ヒドロキシ酪酸とのエステル
CA2658797A1 (en) Derivatives of 4-trimethylammonium-3-aminobutyrate and 4-trimethylphosphonium-3-aminobutyrate as cpt-inhibitors
US8940793B2 (en) 4-[(haloalkyl)(dimethyl)ammonio]butanoates and use thereof in the treatment of cardiovascular disease
US7345190B2 (en) Carnitine conjugates as dual prodrugs and uses thereof
NZ616467B2 (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
US20080188444A1 (en) Methods of treating various diseases using carnitine conjugates as dual prodrugs
CZ284755B6 (cs) Acetylsalicyloyl-L-karnitin a způsob jeho výroby
SK280172B6 (sk) Salicyloylkarnitín a spôsob jeho výroby

Legal Events

Date Code Title Description
AS Assignment

Owner name: JSC GRINDEKS, LATVIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KALVINS, IVARS;LIEPINS, EDGARS;LOZA, EINARS;AND OTHERS;REEL/FRAME:032057/0596

Effective date: 20131020

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION